LYEL (Lyell Immunopharma) EPS (Basic) : $-1.24 (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lyell Immunopharma EPS (Basic)?

Lyell Immunopharma's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was $-0.65. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.24.

Lyell Immunopharma's EPS (Diluted) for the three months ended in Dec. 2024 was $-0.65. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.24.

Lyell Immunopharma's EPS without NRI for the three months ended in Dec. 2024 was $-0.16. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.70.

During the past 3 years, the average EPS without NRI Growth Rate was 22.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Lyell Immunopharma's highest 3-Year average EPS without NRI Growth Rate was 22.50% per year. The lowest was -5.60% per year. And the median was 3.10% per year.

Lyell Immunopharma EPS (Basic) Historical Data

The historical data trend for Lyell Immunopharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyell Immunopharma EPS (Basic) Chart

Lyell Immunopharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-0.98

-1.84

-0.74

-0.93

-1.31

Lyell Immunopharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.20	-0.24	-0.18	-0.17	-0.65

Lyell Immunopharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Lyell Immunopharma's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-342.994	-	0)	/	261.480
	=	-1.31

Lyell Immunopharma's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-191.935	-	0)	/	279.951
	=	-0.69

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.24

Lyell Immunopharma (NAS:LYEL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lyell Immunopharma EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Lyell Immunopharma's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyell Immunopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyell Immunopharma Inc (NAS:LYEL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskins Way, South San Francisco, CA, USA, 94080

Website

https://www.lyell.com

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Executives

Charles W. Newton	officer: Chief Financial Officer	46 FREDRICK AVENUE, ATHERTON CA 94027
Lynn Seely	director	501 2ND STREET, SUITE 211, SAN FRANCISCO CA 94107
Richard Klausner	director, officer: Executive Chairman	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Matthew Lang	officer: Chief Business Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rahsaan Thompson	officer: Chief Legal Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Tina M. Albertson	officer: Chief Medical Officer	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Gary K. Lee	officer: Chief Scientific Officer	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Cathy Friedman	director	C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Arch Venture Fund Ix Overage, L.p.	10 percent owner	8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Elizabeth Homans	director, officer: Chief Executive Officer	C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Stephen J. Hill	officer: Chief Technical Ops. Officer	C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Elizabeth G Nabel	director	BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
William Jl Rieflin	director	NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Arch Venture Partners Ix, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631